Respiratory diseases, common examples of which include asthma and chronic obstructive pulmonary disease (COPD), affect one in five people in the UK.1 The economic burden of these
AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after confirming he was under investigation last week.
GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
A trial of AstraZeneca and Avillion's first-in-class asthma rescue inhaler Airsupra has been halted early after the drug outperformed a standard therapy.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.